Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-10-31

AUTHORS

Erik Landfeldt, Lars Alfredsson, Volker Straub, Hanns Lochmüller, Katharine Bushby, Peter Lindgren

ABSTRACT

BACKGROUND: Several treatments are on the horizon for Duchenne muscular dystrophy (DMD), a terminal orphan disease. In many jurisdictions, decisions regarding pricing and reimbursement of these health technologies comprise evidence of value for money. OBJECTIVE: The objective of this study was to develop a cost-effectiveness model based on the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT), a new rating scale created specifically to measure disease progression in clinical practice and trials and model DMD in economic evaluations, and compare it with two alternative model structures. METHODS: We constructed three Markov cohort state-transition models to evaluate the cost-effectiveness of a hypothetical intervention for DMD versus standard of care in a UK setting. Model I was based on the DMDSAT, model II on stages of disease as defined in the DMD clinical care guidelines and model III on patients' ventilation status. The conceptual model structures were formulated in collaboration with three DMD experts. RESULTS: All three models were judged to have good validity with regards to the appropriateness of the choice of modelling technique, conceptual representation of the disease, model input data and model outcomes. Across frameworks, lifetime direct medical costs with standard of care ranged between £217,510 and £284,640, total costs between £624,240 and £713,840, and total number of quality-adjusted life-years between 5.96 and 7.17. CONCLUSIONS: We present a first version of a model for the economic evaluation of treatments for DMD based on the DMDSAT, as well as two alternative frameworks encompassing conventional staging of disease progression. Our findings should be helpful to inform health technology assessments and health economic programmes of future treatments for DMD. More... »

PAGES

249-258

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40273-016-0461-5

DOI

http://dx.doi.org/10.1007/s40273-016-0461-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017427938

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27798808


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Care Costs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Markov Chains", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Economic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Muscular Dystrophy, Duchenne", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Practice Guidelines as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality-Adjusted Life Years", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rare Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Technology Assessment, Biomedical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Environmental Medicine, Karolinska Institutet, Nobels v\u00e4g 13, 17177 Stockholm, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.4714.6", 
          "name": [
            "Institute of Environmental Medicine, Karolinska Institutet, Nobels v\u00e4g 13, 17177 Stockholm, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Landfeldt", 
        "givenName": "Erik", 
        "id": "sg:person.01126270611.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126270611.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Environmental Medicine, Karolinska Institutet, Nobels v\u00e4g 13, 17177 Stockholm, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.4714.6", 
          "name": [
            "Institute of Environmental Medicine, Karolinska Institutet, Nobels v\u00e4g 13, 17177 Stockholm, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alfredsson", 
        "givenName": "Lars", 
        "id": "sg:person.0755300735.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755300735.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Newcastle University John Walton Muscular Dystrophy Research Centre and MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK", 
          "id": "http://www.grid.ac/institutes/grid.1006.7", 
          "name": [
            "Newcastle University John Walton Muscular Dystrophy Research Centre and MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Straub", 
        "givenName": "Volker", 
        "id": "sg:person.013561026457.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013561026457.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Newcastle University John Walton Muscular Dystrophy Research Centre and MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK", 
          "id": "http://www.grid.ac/institutes/grid.1006.7", 
          "name": [
            "Newcastle University John Walton Muscular Dystrophy Research Centre and MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lochm\u00fcller", 
        "givenName": "Hanns", 
        "id": "sg:person.015416721437.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015416721437.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Newcastle University John Walton Muscular Dystrophy Research Centre and MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK", 
          "id": "http://www.grid.ac/institutes/grid.1006.7", 
          "name": [
            "Newcastle University John Walton Muscular Dystrophy Research Centre and MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bushby", 
        "givenName": "Katharine", 
        "id": "sg:person.010145544672.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010145544672.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Swedish Institute for Health Economics, Lund, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.416779.a", 
          "name": [
            "Department of Learning, Informatics, Management and Ethics, Medical Management Centre, Karolinska Institutet, Stockholm, Sweden", 
            "The Swedish Institute for Health Economics, Lund, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lindgren", 
        "givenName": "Peter", 
        "id": "sg:person.0674735130.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674735130.62"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40273-015-0327-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051397787", 
          "https://doi.org/10.1007/s40273-015-0327-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd3160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052467686", 
          "https://doi.org/10.1038/nrd3160"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00415-016-8080-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034011540", 
          "https://doi.org/10.1007/s00415-016-8080-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7525-1-54", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023782676", 
          "https://doi.org/10.1186/1477-7525-1-54"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-014-0560-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035914431", 
          "https://doi.org/10.1007/s10198-014-0560-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1750-1172-9-62", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028764826", 
          "https://doi.org/10.1186/1750-1172-9-62"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40258-012-0004-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031549059", 
          "https://doi.org/10.1007/s40258-012-0004-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1750-1172-7-74", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021716479", 
          "https://doi.org/10.1186/1750-1172-7-74"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-10-31", 
    "datePublishedReg": "2016-10-31", 
    "description": "BACKGROUND: Several treatments are on the horizon for Duchenne muscular dystrophy (DMD), a terminal orphan disease. In many jurisdictions, decisions regarding pricing and reimbursement of these health technologies comprise evidence of value for money.\nOBJECTIVE: The objective of this study was to develop a cost-effectiveness model based on the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT), a new rating scale created specifically to measure disease progression in clinical practice and trials and model DMD in economic evaluations, and compare it with two alternative model structures.\nMETHODS: We constructed three Markov cohort state-transition models to evaluate the cost-effectiveness of a hypothetical intervention for DMD versus standard of care in a UK setting. Model\u00a0I was based on the DMDSAT, model\u00a0II on stages of disease as defined in the DMD clinical care guidelines and model\u00a0III on patients' ventilation status. The conceptual model structures were formulated in collaboration with three DMD experts.\nRESULTS: All three models were judged to have good validity with regards to the appropriateness of the choice of modelling technique, conceptual representation of the disease, model input data and model outcomes. Across frameworks, lifetime direct medical costs with standard of care ranged between \u00a3217,510 and \u00a3284,640, total costs between \u00a3624,240 and \u00a3713,840, and total number of quality-adjusted life-years between 5.96 and 7.17.\nCONCLUSIONS: We present a first version of a model for the economic evaluation of treatments for DMD based on the DMDSAT, as well as two alternative frameworks encompassing conventional staging of disease progression. Our findings should be helpful to inform health technology assessments and health economic programmes of future treatments for DMD.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40273-016-0461-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "keywords": [
      "economic evaluation", 
      "Markov cohort state-transition model", 
      "cohort state-transition model", 
      "Duchenne muscular dystrophy", 
      "lifetime direct medical costs", 
      "cost-effectiveness model", 
      "cost-effectiveness analysis", 
      "standard of care", 
      "model Duchenne muscular dystrophy", 
      "economic program", 
      "evidence of value", 
      "direct medical costs", 
      "disease progression", 
      "health technology assessment", 
      "ventilation status", 
      "state transition model", 
      "conceptual model structure", 
      "hypothetical intervention", 
      "alternative framework", 
      "muscular dystrophy", 
      "stage of disease", 
      "clinical care guidelines", 
      "model framework", 
      "model structure", 
      "model outcomes", 
      "UK setting", 
      "total cost", 
      "health technologies", 
      "medical costs", 
      "technology assessment", 
      "care guidelines", 
      "conventional staging", 
      "alternative model structures", 
      "future treatment", 
      "clinical practice", 
      "cost", 
      "orphan disease", 
      "Rating Scale", 
      "self-assessment tool", 
      "pricing", 
      "disease", 
      "new rating scale", 
      "good validity", 
      "money", 
      "treatment", 
      "framework", 
      "progression", 
      "care", 
      "dystrophy", 
      "model", 
      "decisions", 
      "reimbursement", 
      "horizon", 
      "total number", 
      "choice", 
      "jurisdictions", 
      "staging", 
      "trials", 
      "evaluation", 
      "intervention", 
      "outcomes", 
      "model input data", 
      "evidence", 
      "standards", 
      "status", 
      "guidelines", 
      "findings", 
      "setting", 
      "assessment", 
      "appropriateness", 
      "objective", 
      "study", 
      "input data", 
      "data", 
      "program", 
      "values", 
      "regard", 
      "analysis", 
      "first version", 
      "stage", 
      "practice", 
      "experts", 
      "technology", 
      "number", 
      "version", 
      "structure", 
      "validity", 
      "scale", 
      "collaboration", 
      "tool", 
      "technique", 
      "representation", 
      "conceptual representation", 
      "terminal orphan disease", 
      "DMDSAT", 
      "muscular dystrophy Functional Ability Self-Assessment Tool", 
      "dystrophy Functional Ability Self-Assessment Tool", 
      "Functional Ability Self-Assessment Tool", 
      "Ability Self-Assessment Tool", 
      "DMD clinical care guidelines", 
      "patients' ventilation status", 
      "DMD experts", 
      "health economic programmes"
    ], 
    "name": "Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis", 
    "pagination": "249-258", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017427938"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40273-016-0461-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27798808"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40273-016-0461-5", 
      "https://app.dimensions.ai/details/publication/pub.1017427938"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_715.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40273-016-0461-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40273-016-0461-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40273-016-0461-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40273-016-0461-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40273-016-0461-5'


 

This table displays all metadata directly associated to this object as RDF triples.

287 TRIPLES      22 PREDICATES      149 URIs      133 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40273-016-0461-5 schema:about N1739c2ae46af40ffb9632f4403b18ca0
2 N277750dca461495e926283b423f28888
3 N38cb6ad7349449158373f901cd6516af
4 N3b933fd798c945e7ad9fdafe9873a7ae
5 N4963ccd8c25749c5af29f62fad4667b1
6 N577da6bbf75c40e8853dfd86c4c3759b
7 N880b7c339e3b4c0cb8540e732a1484ca
8 N886a41b327d744c8a23902f22ad66baf
9 N923dfc2c8720478a9149dfde4ca08f48
10 Na6adf495b3134869b9cbd5bacbb800e4
11 Nae4a0ee0fcec4ebbbcef7d767ce6493d
12 Nb3d482119245454e851f883107ac7997
13 anzsrc-for:14
14 anzsrc-for:1402
15 schema:author Ne57c762dd08749d49b6bdb2cbbd3228b
16 schema:citation sg:pub.10.1007/s00415-016-8080-9
17 sg:pub.10.1007/s10198-014-0560-1
18 sg:pub.10.1007/s40258-012-0004-y
19 sg:pub.10.1007/s40273-015-0327-2
20 sg:pub.10.1038/nrd3160
21 sg:pub.10.1186/1477-7525-1-54
22 sg:pub.10.1186/1750-1172-7-74
23 sg:pub.10.1186/1750-1172-9-62
24 schema:datePublished 2016-10-31
25 schema:datePublishedReg 2016-10-31
26 schema:description BACKGROUND: Several treatments are on the horizon for Duchenne muscular dystrophy (DMD), a terminal orphan disease. In many jurisdictions, decisions regarding pricing and reimbursement of these health technologies comprise evidence of value for money. OBJECTIVE: The objective of this study was to develop a cost-effectiveness model based on the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT), a new rating scale created specifically to measure disease progression in clinical practice and trials and model DMD in economic evaluations, and compare it with two alternative model structures. METHODS: We constructed three Markov cohort state-transition models to evaluate the cost-effectiveness of a hypothetical intervention for DMD versus standard of care in a UK setting. Model I was based on the DMDSAT, model II on stages of disease as defined in the DMD clinical care guidelines and model III on patients' ventilation status. The conceptual model structures were formulated in collaboration with three DMD experts. RESULTS: All three models were judged to have good validity with regards to the appropriateness of the choice of modelling technique, conceptual representation of the disease, model input data and model outcomes. Across frameworks, lifetime direct medical costs with standard of care ranged between £217,510 and £284,640, total costs between £624,240 and £713,840, and total number of quality-adjusted life-years between 5.96 and 7.17. CONCLUSIONS: We present a first version of a model for the economic evaluation of treatments for DMD based on the DMDSAT, as well as two alternative frameworks encompassing conventional staging of disease progression. Our findings should be helpful to inform health technology assessments and health economic programmes of future treatments for DMD.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf Na77c54f059184feb92e3df885d4ecb16
31 Nb93f09aadcb04b7b95ec15e42facef5a
32 sg:journal.1102812
33 schema:keywords Ability Self-Assessment Tool
34 DMD clinical care guidelines
35 DMD experts
36 DMDSAT
37 Duchenne muscular dystrophy
38 Functional Ability Self-Assessment Tool
39 Markov cohort state-transition model
40 Rating Scale
41 UK setting
42 alternative framework
43 alternative model structures
44 analysis
45 appropriateness
46 assessment
47 care
48 care guidelines
49 choice
50 clinical care guidelines
51 clinical practice
52 cohort state-transition model
53 collaboration
54 conceptual model structure
55 conceptual representation
56 conventional staging
57 cost
58 cost-effectiveness analysis
59 cost-effectiveness model
60 data
61 decisions
62 direct medical costs
63 disease
64 disease progression
65 dystrophy
66 dystrophy Functional Ability Self-Assessment Tool
67 economic evaluation
68 economic program
69 evaluation
70 evidence
71 evidence of value
72 experts
73 findings
74 first version
75 framework
76 future treatment
77 good validity
78 guidelines
79 health economic programmes
80 health technologies
81 health technology assessment
82 horizon
83 hypothetical intervention
84 input data
85 intervention
86 jurisdictions
87 lifetime direct medical costs
88 medical costs
89 model
90 model Duchenne muscular dystrophy
91 model framework
92 model input data
93 model outcomes
94 model structure
95 money
96 muscular dystrophy
97 muscular dystrophy Functional Ability Self-Assessment Tool
98 new rating scale
99 number
100 objective
101 orphan disease
102 outcomes
103 patients' ventilation status
104 practice
105 pricing
106 program
107 progression
108 regard
109 reimbursement
110 representation
111 scale
112 self-assessment tool
113 setting
114 stage
115 stage of disease
116 staging
117 standard of care
118 standards
119 state transition model
120 status
121 structure
122 study
123 technique
124 technology
125 technology assessment
126 terminal orphan disease
127 tool
128 total cost
129 total number
130 treatment
131 trials
132 validity
133 values
134 ventilation status
135 version
136 schema:name Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
137 schema:pagination 249-258
138 schema:productId N1e76065985cf4a6085929225e9e59188
139 N441b64eb8f10490aa2f7992c8235bab9
140 N87ac21f3f1e748dabbb834715140ad91
141 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017427938
142 https://doi.org/10.1007/s40273-016-0461-5
143 schema:sdDatePublished 2021-12-01T19:38
144 schema:sdLicense https://scigraph.springernature.com/explorer/license/
145 schema:sdPublisher N364b155266354bdcb820c1c634337b0f
146 schema:url https://doi.org/10.1007/s40273-016-0461-5
147 sgo:license sg:explorer/license/
148 sgo:sdDataset articles
149 rdf:type schema:ScholarlyArticle
150 N1739c2ae46af40ffb9632f4403b18ca0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Models, Economic
152 rdf:type schema:DefinedTerm
153 N1e76065985cf4a6085929225e9e59188 schema:name pubmed_id
154 schema:value 27798808
155 rdf:type schema:PropertyValue
156 N277750dca461495e926283b423f28888 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name United Kingdom
158 rdf:type schema:DefinedTerm
159 N29470a50e61449e58bd1cb714ccee628 rdf:first sg:person.015416721437.85
160 rdf:rest N338415cdc8ca4130aa0ac23de6f97abd
161 N338415cdc8ca4130aa0ac23de6f97abd rdf:first sg:person.010145544672.19
162 rdf:rest N9aab9dd36d5448bab583c2d891902f42
163 N364b155266354bdcb820c1c634337b0f schema:name Springer Nature - SN SciGraph project
164 rdf:type schema:Organization
165 N38cb6ad7349449158373f901cd6516af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Humans
167 rdf:type schema:DefinedTerm
168 N3b933fd798c945e7ad9fdafe9873a7ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Disease Progression
170 rdf:type schema:DefinedTerm
171 N441b64eb8f10490aa2f7992c8235bab9 schema:name dimensions_id
172 schema:value pub.1017427938
173 rdf:type schema:PropertyValue
174 N4963ccd8c25749c5af29f62fad4667b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Rare Diseases
176 rdf:type schema:DefinedTerm
177 N577da6bbf75c40e8853dfd86c4c3759b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Muscular Dystrophy, Duchenne
179 rdf:type schema:DefinedTerm
180 N7a5b267691454186922156b7450a6841 rdf:first sg:person.0755300735.43
181 rdf:rest Ne302fe82afe04ec2be07c0fa8f2765ca
182 N87ac21f3f1e748dabbb834715140ad91 schema:name doi
183 schema:value 10.1007/s40273-016-0461-5
184 rdf:type schema:PropertyValue
185 N880b7c339e3b4c0cb8540e732a1484ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Practice Guidelines as Topic
187 rdf:type schema:DefinedTerm
188 N886a41b327d744c8a23902f22ad66baf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Quality-Adjusted Life Years
190 rdf:type schema:DefinedTerm
191 N923dfc2c8720478a9149dfde4ca08f48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Technology Assessment, Biomedical
193 rdf:type schema:DefinedTerm
194 N9aab9dd36d5448bab583c2d891902f42 rdf:first sg:person.0674735130.62
195 rdf:rest rdf:nil
196 Na6adf495b3134869b9cbd5bacbb800e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Health Care Costs
198 rdf:type schema:DefinedTerm
199 Na77c54f059184feb92e3df885d4ecb16 schema:volumeNumber 35
200 rdf:type schema:PublicationVolume
201 Nae4a0ee0fcec4ebbbcef7d767ce6493d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Cost-Benefit Analysis
203 rdf:type schema:DefinedTerm
204 Nb3d482119245454e851f883107ac7997 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Markov Chains
206 rdf:type schema:DefinedTerm
207 Nb93f09aadcb04b7b95ec15e42facef5a schema:issueNumber 2
208 rdf:type schema:PublicationIssue
209 Ne302fe82afe04ec2be07c0fa8f2765ca rdf:first sg:person.013561026457.82
210 rdf:rest N29470a50e61449e58bd1cb714ccee628
211 Ne57c762dd08749d49b6bdb2cbbd3228b rdf:first sg:person.01126270611.82
212 rdf:rest N7a5b267691454186922156b7450a6841
213 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
214 schema:name Economics
215 rdf:type schema:DefinedTerm
216 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
217 schema:name Applied Economics
218 rdf:type schema:DefinedTerm
219 sg:journal.1102812 schema:issn 1170-7690
220 1179-2027
221 schema:name PharmacoEconomics
222 schema:publisher Springer Nature
223 rdf:type schema:Periodical
224 sg:person.010145544672.19 schema:affiliation grid-institutes:grid.1006.7
225 schema:familyName Bushby
226 schema:givenName Katharine
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010145544672.19
228 rdf:type schema:Person
229 sg:person.01126270611.82 schema:affiliation grid-institutes:grid.4714.6
230 schema:familyName Landfeldt
231 schema:givenName Erik
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126270611.82
233 rdf:type schema:Person
234 sg:person.013561026457.82 schema:affiliation grid-institutes:grid.1006.7
235 schema:familyName Straub
236 schema:givenName Volker
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013561026457.82
238 rdf:type schema:Person
239 sg:person.015416721437.85 schema:affiliation grid-institutes:grid.1006.7
240 schema:familyName Lochmüller
241 schema:givenName Hanns
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015416721437.85
243 rdf:type schema:Person
244 sg:person.0674735130.62 schema:affiliation grid-institutes:grid.416779.a
245 schema:familyName Lindgren
246 schema:givenName Peter
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674735130.62
248 rdf:type schema:Person
249 sg:person.0755300735.43 schema:affiliation grid-institutes:grid.4714.6
250 schema:familyName Alfredsson
251 schema:givenName Lars
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755300735.43
253 rdf:type schema:Person
254 sg:pub.10.1007/s00415-016-8080-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034011540
255 https://doi.org/10.1007/s00415-016-8080-9
256 rdf:type schema:CreativeWork
257 sg:pub.10.1007/s10198-014-0560-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035914431
258 https://doi.org/10.1007/s10198-014-0560-1
259 rdf:type schema:CreativeWork
260 sg:pub.10.1007/s40258-012-0004-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1031549059
261 https://doi.org/10.1007/s40258-012-0004-y
262 rdf:type schema:CreativeWork
263 sg:pub.10.1007/s40273-015-0327-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051397787
264 https://doi.org/10.1007/s40273-015-0327-2
265 rdf:type schema:CreativeWork
266 sg:pub.10.1038/nrd3160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052467686
267 https://doi.org/10.1038/nrd3160
268 rdf:type schema:CreativeWork
269 sg:pub.10.1186/1477-7525-1-54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023782676
270 https://doi.org/10.1186/1477-7525-1-54
271 rdf:type schema:CreativeWork
272 sg:pub.10.1186/1750-1172-7-74 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021716479
273 https://doi.org/10.1186/1750-1172-7-74
274 rdf:type schema:CreativeWork
275 sg:pub.10.1186/1750-1172-9-62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028764826
276 https://doi.org/10.1186/1750-1172-9-62
277 rdf:type schema:CreativeWork
278 grid-institutes:grid.1006.7 schema:alternateName Newcastle University John Walton Muscular Dystrophy Research Centre and MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
279 schema:name Newcastle University John Walton Muscular Dystrophy Research Centre and MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
280 rdf:type schema:Organization
281 grid-institutes:grid.416779.a schema:alternateName The Swedish Institute for Health Economics, Lund, Sweden
282 schema:name Department of Learning, Informatics, Management and Ethics, Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
283 The Swedish Institute for Health Economics, Lund, Sweden
284 rdf:type schema:Organization
285 grid-institutes:grid.4714.6 schema:alternateName Institute of Environmental Medicine, Karolinska Institutet, Nobels väg 13, 17177 Stockholm, Sweden
286 schema:name Institute of Environmental Medicine, Karolinska Institutet, Nobels väg 13, 17177 Stockholm, Sweden
287 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...